Abstract:Gliomas, particularly high-grade gliomas including glioblastoma (GBM), represent the most common and malignant types of primary brain cancer in adults, and carry a poor prognosis. GBM has been classified into distinct subgroups over the years based on cellular morphology, clinical characteristics, biomarkers, and neuroimaging findings. Based on these classifications, differences in therapeutic response and patient outcomes have been established. Recently, the identification of complex molecular signatures of GBM has led to the development of diverse targeted therapeutic regimens and translation into multiple clinical trials. Chemical-, peptide-, antibody-, and nanoparticle-based probes have been designed to target specific molecules in gliomas and then be visualized with multimodality molecular imaging (MI) techniques including positron emission tomography (PET), single-photon emission computed tomography (SPECT), near-infrared fluorescence (NIRF), bioluminescence imaging (BLI), and magnetic resonance imaging (MRI). Thus, multiple molecules of interest can now be noninvasively imaged to guide targeted therapies with a potential survival benefit. Here, we review developments in molecular-targeted diagnosis and therapy in glioma, MI of these targets, and MI monitoring of treatment response, with a focus on the biological mechanisms of these advanced molecular probes. MI probes have the potential to noninvasively demonstrate the pathophysiologic features of glioma for diagnostic, treatment, and response assessment considerations for various targeted therapies, including immunotherapy. However, most MI tracers are in preclinical development, with only integrin αVβ3 and isocitrate dehydrogenase (IDH)-mutant MI tracers having been translated to patients. Expanded international collaborations would accelerate translational research in the field of glioma MI.

Advances in Magnetic Resonance Imaging Contrast Agents for Glioblastoma-Targeting Theranostics

Recent development of contrast agents for magnetic resonance and multimodal imaging of glioblastoma

Gadolinium-based contrast agents for tumor targeting imaging

Mechanical Nanosurgery of Chemoresistant Glioblastoma Using Magnetically Controlled Carbon Nanotubes

Advanced Imaging Techniques for Differentiating Pseudoprogression and Tumor Recurrence After Immunotherapy for Glioblastoma

Image‐guided Diagnosis and Treatment of Glioblastoma

Advances in nanotechnology for the treatment of GBM

The art of attraction: applications of multifunctional magnetic nanomaterials for malignant glioma

Advances in Brain Tumor Therapy Based on the Magnetic Nanoparticles

Visualization of Diagnostic and Therapeutic Targets in Glioma With Molecular Imaging

Nanoradiosensitizers in glioblastoma treatment: recent advances and future perspectives

Advances in Nanotechnology-Based Immunotherapy for Glioblastoma

Deep Penetrating and Sensitive Targeted Magnetic Particle Imaging and Photothermal Therapy of Early-Stage Glioblastoma Based on a Biomimetic Nanoplatform.

Organic Small Molecule Contrast Agent for Targeted Photoacoustic Imaging of Patient‐Derived Brain Tumors

Dual-targeting upconversion nanoprobes across the blood-brain barrier for magnetic resonance/fluorescence imaging of intracranial glioblastoma.

Magnetic Nanoparticles for MRI of Brain Tumors.

Construction of nanomaterials as contrast agents or probes for glioma imaging

Biomimetic Nanocomposites for Glioma Imaging and Therapy

A transferrin receptor targeting dual-modal MR/NIR fluorescent imaging probe for glioblastoma diagnosis

Blood-Brain Barrier Conquest in Glioblastoma Nanomedicine: Strategies, Clinical Advances, and Emerging Challenges

Targeted Theranostic Nanoparticles for Brain Tumor Treatment